Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab vs Aflibercept in nAMD
NCT04882956Unknown
- Sponsor
- Benha University
- Start
- Aug 2020
- Primary completion
- Dec 2021
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised trial of brolucizumab in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Benha University. Primary endpoint: Best Corrected Visual Acuity at 12 months. Status: unknown.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04882956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04882956.